Bank of New York Mellon Corp Purchases Shares of 116,658 TScan Therapeutics, Inc. (NASDAQ:TCRX)

Bank of New York Mellon Corp acquired a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 116,658 shares of the company’s stock, valued at approximately $682,000. Bank of New York Mellon Corp owned approximately 0.22% of TScan Therapeutics as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in TCRX. Tocqueville Asset Management L.P. bought a new stake in TScan Therapeutics in the 1st quarter valued at $1,685,000. Vanguard Group Inc. lifted its stake in shares of TScan Therapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after buying an additional 20,000 shares during the last quarter. Cannon Global Investment Management LLC acquired a new stake in shares of TScan Therapeutics during the 1st quarter worth about $139,000. Finally, Pale Fire Capital SE boosted its holdings in shares of TScan Therapeutics by 30.2% during the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock worth $126,000 after buying an additional 4,998 shares during the period. Institutional investors and hedge funds own 82.83% of the company’s stock.

Insider Activity

In related news, Director Barbara Klencke purchased 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $5.53 per share, with a total value of $27,650.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at $221,200. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other TScan Therapeutics news, insider Zoran Zdraveski sold 164,686 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the transaction, the insider now owns 4,716 shares in the company, valued at approximately $27,258.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barbara Klencke purchased 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was bought at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at $221,200. The disclosure for this purchase can be found here. Company insiders own 2.76% of the company’s stock.

TScan Therapeutics Stock Down 2.1 %

TScan Therapeutics stock opened at $5.52 on Monday. The firm has a market capitalization of $291.80 million, a price-to-earnings ratio of -4.31 and a beta of 0.79. The firm’s fifty day moving average price is $6.14 and its two-hundred day moving average price is $7.06. TScan Therapeutics, Inc. has a 1-year low of $2.43 and a 1-year high of $9.69. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. The firm had revenue of $0.54 million for the quarter, compared to the consensus estimate of $1.55 million. On average, equities research analysts predict that TScan Therapeutics, Inc. will post -1.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research report on Monday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Finally, Wedbush reissued an “outperform” rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Monday, August 12th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.